HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.
Advertisement
Set Alert for Articles By Bowman Cox

Latest From Bowman Cox

FDA Gives Firms One Month To Fix Listings Before Barring Drugs From US Market

Tens of thousands of listed drugs could be barred if manufacturers do not update their records.

Manufacturing Compliance

ICH Hires Trainers As Emerging Authorities Strive To Harmonize

ICH prepares to lift veil on global regulatory harmonization progress as it hires trainers to speed up the process.

Quality International

FDA's Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Democratic senators push data-challenged gene therapy into maw of drug pricing debate as they press acting commissioner Sharpless to bring the hammer down on Novartis, but also question US FDA's decision to withdraw the proposed rule last year.

Quality Gene Therapy

Key Senator Hinges Support For Cheap Drug Imports On Surprise Inspections

More unannounced inspections abroad would warm Senate Finance Committee chairman to President Trump's drug importation plan.

Quality Compliance

Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm

After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?

Manufacturing Quality

US FDA Drops Plan To Simplify Pharmaceutical Plant Reporting

Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.

Manufacturing Quality
See All
Advertisement
UsernamePublicRestriction

Register